A retrospective study of cytomegalovirus pneumonia in renal transplant patients
A retrospective study of cytomegalovirus pneumonia in renal transplant patients
复制标题
肾移植患者巨细胞病毒肺炎的回顾性研究
DOI：
10.3892/etm.2014.1577
复制
发表时间：
2014-05-01
影响因子：
2.7
通讯作者：
Fu, Yaowen
中科院分区：
文献类型：
--
作者：
Dong, Biao;Wang, Yuantao;Fu, Yaowen
本研究的目的是探讨肾移植受者巨细胞病毒（CMV）肺炎的最佳预防方法。共有83名2008年1月至2011年12月期间被诊断患有巨细胞病毒肺炎的肾移植受者参加了这项研究。根据所采取的预防措施，将患者分配到标准组或改进组。回顾性研究比较两组巨细胞病毒肺炎的发生率、治愈率或康复率以及死亡率。结果表明，长期口服更昔洛韦预防可以有效降低肾移植受者发生巨细胞病毒肺炎的风险。治疗，包括早期停用免疫抑制剂、定期使用糖皮质激素和仔细的支持治疗，有助于控制巨细胞病毒肺炎。此外，在接受适当预防[口服更昔洛韦和甲氧苄啶-磺胺甲恶唑 (SMZ-TMP) 3 个月疗程]的肾脏受者中，抗体诱导治疗可能不会增加 CMV 肺炎的风险。因此，本研究表明，长期口服更昔洛韦预防、停用免疫抑制剂和定期使用糖皮质激素可能会改善巨细胞病毒肺炎的治疗。
The aim of the present study was to investigate an optimal prophylaxis of cytomegalovirus (CMV) pneumonia in renal transplant recipients. A total of 83 kidney transplant recipients who had been diagnosed with CMV pneumonia between January 2008 and December 2011 were enrolled in the study. Patients were assigned to a standard or improved group based on the prophylaxis administered. The retrospective study was undertaken to compare the incidence of CMV pneumonia, cure rate or recovery rate and mortality between the two groups. The results indicated that a longer duration of prophylaxis with oral ganciclovir effectively reduced the risk of CMV pneumonia in kidney transplant recipients. Treatments, including early withdrawal of immunosuppressants, regular use of glucocorticosteroids and careful supportive therapy, were beneficial in controlling CMV pneumonia. Furthermore, antibody induction therapy may not increase the risk of CMV pneumonia in kidney recipients administered proper prophylaxis [3-month course of oral ganciclovir and trimethoprim-sulfamethoxazole (SMZ-TMP)]. Therefore, the present study demonstrated that a longer duration of prophylaxis with oral ganciclovir, withdrawal of immunosuppressants and regular use of glucocorticosteroids may be improved treatments for CMV pneumonia.